Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alx Oncology Holdings (ALXO) Operating Expenses (2019 - 2026)

Alx Oncology Holdings' Operating Expenses history spans 5 years, with the latest figure at $48.0 million for Q4 2023.

  • On a quarterly basis, Operating Expenses rose 49.05% to $48.0 million in Q4 2023 year-over-year; TTM through Dec 2023 was $170.3 million, a 33.62% increase, with the full-year FY2025 number at $104.0 million, down 26.99% from a year prior.
  • Operating Expenses hit $48.0 million in Q4 2023 for Alx Oncology Holdings, down from $53.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for ALXO hit a ceiling of $53.3 million in Q3 2023 and a floor of $4.3 million in Q3 2019.
  • Historically, Operating Expenses has averaged $23.4 million across 5 years, with a median of $24.6 million in 2021.
  • Biggest five-year swings in Operating Expenses: surged 150.55% in 2021 and later rose 8.84% in 2023.
  • Tracing ALXO's Operating Expenses over 5 years: stood at $8.9 million in 2019, then skyrocketed by 99.25% to $17.8 million in 2020, then skyrocketed by 59.73% to $28.5 million in 2021, then increased by 13.16% to $32.2 million in 2022, then skyrocketed by 49.05% to $48.0 million in 2023.
  • Business Quant data shows Operating Expenses for ALXO at $48.0 million in Q4 2023, $53.3 million in Q3 2023, and $36.8 million in Q2 2023.